drugset / Trial / NCT02022254

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

NCT02022254 ↗

Phase 1 Completed 24 enrolled Novo Nordisk A/S
CrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe and Asia. The aim of the trial is to investigate the influence of semaglutide on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin and pharmacokinetics of metformin in healthy subjects.

Timeline

Start
2013-12-17
Primary completion
2014-08-28
Completion
2014-08-28

Outcome

Met primary endpoint

paper Estimated area under the plasma concentration-time curve ratios for all concomitant medications before and with semaglutide treatment were within the pre-specified interval. PMID 28349387 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject Semaglutide Peptide 1 mg Subcutaneous
Subject Warfarin Small molecule 25 mg Oral